UB Paderborn / Katalog / Suche / in CDI

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

The Lancet (British edition), 2017-09, Vol.390 (10100), p.1260-1344

2017

Link zum Volltext

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

The New England journal of medicine, 2021-06, Vol.384 (25), p.2394-2405

2021

Link zum Volltext

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

The Lancet (British edition), 2021-10, Vol.398 (10308), p.1344-1357

2021

Link zum Volltext

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

The New England journal of medicine, 2021-04, Vol.384 (13), p.1191-1203

2021

Link zum Volltext

Emerging concepts in the science of vaccine adjuvants

Nature reviews. Drug discovery, 2021-06, Vol.20 (6), p.454-475

2021

Link zum Volltext

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

The Lancet (British edition), 2017-03, Vol.389 (10073), p.1011-1024

2017

Link zum Volltext

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Lancet, 2018-11, Vol.392 (10159), p.1859-1922

2018

Link zum Volltext

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

The New England journal of medicine, 2018-12, Vol.379 (25), p.2395-2406

2018

Link zum Volltext

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

The Lancet infectious diseases, 2019-01, Vol.19 (1), p.56-66

2019

Link zum Volltext

Employee adjustment and well-being in the era of COVID-19: Implications for human resource management

Journal of business research, 2020-08, Vol.116, p.183-187

2020

Link zum Volltext

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1403

2021

Link zum Volltext

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

The New England journal of medicine, 2021-06, Vol.384 (22), p.2102-2114

2021

Link zum Volltext

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.111-121

2018

Link zum Volltext

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

The New England journal of medicine, 2022-06, Vol.386 (24), p.2261-2272

2022

Link zum Volltext

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019

JAMA oncology, 2022-03, Vol.8 (3), p.420

2022

Link zum Volltext

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

The New England journal of medicine, 2021-08, Vol.385 (8), p.683-694

2021

Link zum Volltext

Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

The Lancet (British edition), 2016, Vol.388 (10053), p.1603-1658

2016

Link zum Volltext

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

The New England journal of medicine, 2018-05, Vol.378 (19), p.1789-1801

2018

Link zum Volltext

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1824-1835

2017

Link zum Volltext

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Journal of clinical oncology, 2020-10, Vol.38 (29), p.3388-3397

2020

Link zum Volltext

COVID-19: Melatonin as a potential adjuvant treatment

Life sciences (1973), 2020-06, Vol.250, p.117583-6, Article 117583

2020

Link zum Volltext

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823

2017

Link zum Volltext

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Nature (London), 2021-07, Vol.595 (7867), p.432-437

2021

Link zum Volltext

1 – 25 von 16.630.905

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(10.922.195)
Mit Volltextzugriff
(13.888.326)

Publikationsform

Artikel
(12.343.800)
Buchkapitel
(1.229.713)
Newsletter-Artikel
(936.023)
magazinearticle
(668.433)
Zeitungsartikel
(663.705)
Tagungsberichte
(274.923)
Reviews
(224.024)
Berichte
(122.430)
Dissertationen
(63.871)
Bücher
(54.560)
Referenzeintrag
(38.722)
Texte
(4.441)
Datensätze
(4.345)
Webseiten
(1.422)
government_documents
(206)
Zeitschriften
(133)
Normen
(83)
Sonstige
(23)
archival_material_manuscripts
(18)
videos
(12)

Sprache

Englisch
(16.311.269)
Japanisch
(1.117.340)
Spanisch
(111.290)
Deutsch
(109.336)
Portugiesisch
(77.127)
Französisch
(68.145)
Chinesisch
(21.710)
Russisch
(14.381)
Koreanisch
(10.981)
Norwegisch
(8.696)
Urdu
(8.037)
Ndonga
(7.888)
Polnisch
(6.513)
Italienisch
(6.420)
Türkisch
(5.041)
Niederländisch
(4.071)
Tschechisch
(3.414)
Ungarisch
(3.188)
Croatian
(3.143)
Rumänisch
(2.369)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7.826.559)
Life Sciences & Biomedicine
(5.063.774)
Humans
(3.113.032)
Female
(1.823.251)
Technology
(1.758.858)
Physical Sciences
(1.706.671)
Male
(1.687.710)
Social Sciences
(1.389.641)
Adult
(1.025.657)
Middle Aged
(994.746)
Animals
(894.984)
Engineering
(889.833)
Biological And Medical Sciences
(887.050)
Aged
(769.974)
Chemistry
(625.184)
Physics
(612.019)
Medical Sciences
(607.536)
Science & Technology - Other Topics
(594.672)
Studies
(575.856)
Risk Factors
(504.469)

Kollektion

Free E-Journal (出版社公開部分のみ）
(5.220.487)
IngentaConnect Journals
(5.000.613)
IngentaConnect Journals
(2.975.394)
Ovid SocietyJournals and Single Titles
(2.817.715)
Nexis Uni
(2.376.744)
Wiley Blackwell Single Titles
(2.031.965)
SpringerLink Journals - AutoHoldings
(1.891.196)
Factiva
(1.864.592)
Publisher website
(1.735.344)
Wiley Online Library
(1.489.045)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(1.260.750)
EBSCOhost Business Source Ultimate
(1.246.892)
Ebook Central Perpetual and DDA
(1.188.433)
eBooks on EBSCOhost
(1.141.163)
Elsevier ScienceDirect Journals
(1.137.859)
JSTOR
(952.607)
Taylor & Francis Current Content Access
(883.237)
Taylor & Francis Journals Complete
(876.038)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(683.407)
SAGE Complete
(595.832)

Zeitschrift / Serie

Pr Newswire
(226.742)
Business Wire
(190.290)
Plos One
(165.860)
Scientific Reports
(100.406)
Mondaq Business Briefing
(61.768)
M2 Presswire
(51.142)
Ft.Com
(48.813)
Journal Of Physics. Conference Series
(47.559)
Journal Of Physics: Conference Series
(43.546)
Sustainability
(41.142)

5 weitere anzeigen...